Edwards Lifesciences (EW) EBT Margin (2009 - 2026)

Edwards Lifesciences has reported EBT Margin for 18 years, with the latest figure at 29.86% in Q2 2026.

• On a quarterly basis, EBT Margin rose 374.0% year-over-year to 29.86% in Q2 2026; TTM through Jun 2026 was 21.77%, a 685.0% decrease from a year earlier, with the FY2025 full-year figure at 20.98%, down 748.0% from the prior year.
• EBT Margin was 29.86% for Q2 2026 at Edwards Lifesciences, up from 27.84% in the prior quarter.
• The five-year high for EBT Margin was 49.17% in Q4 2022, with the low at 5.76% in Q4 2025.
• Average EBT Margin over 5 years is 28.74%, with a median of 29.37% recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT Margin surged 2087 bps in 2022, then slumped 2239 bps in 2025.
• Over 5 years, EBT Margin stood at 49.17% in 2022, then slumped by 41 bps to 29.0% in 2023, then declined by 3 bps to 28.15% in 2024, then tumbled by 80 bps to 5.76% in 2025, then jumped by 418 bps to 29.86% in 2026.
• The last three EBT Margin figures came in at 29.86% (Q2 2026), 27.84% (Q1 2026), and 5.76% (Q4 2025), per Business Quant data.